Thursday, July 9, 2026

pharma · Social Anxiety Disorder · Drug Drug Interaction · VTGN

Vistagen Therapeutics

Vesigen Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker VTGN. Primary therapeutic focus areas include Social Anxiety Disorder, Drug Drug Interaction, Major Depressive

Cambridge, USA HQ
7 Employees
Public company Type
VTGN · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Employees
7
Programs
10
Drugs
3
Patents
6
Clinical program

Fasedienol Nasal Spray

Phase 3 · small molecule · Social Anxiety Disorder (SAD)

Fasedienol Nasal Spray for Social Anxiety Disorder (SAD) is a Phase 3 program (small_molecule) at Vistagen Therapeutics with 1 ClinicalTrials.gov record(s).

← All Vistagen Therapeutics projects Phase 3 small molecule active

Internal code PH94B-CL043

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Vistagen Therapeutics
Phase
Phase 3
Modality
small_molecule
Indication
Social Anxiety Disorder (SAD)
Status
active
Trials
1

Clinical trials